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Synovial sarcoma shows a characteristic t(X;18) translocation but not the expected female predominance in incidence. We
speculate that, among females, one X-chromosome is inactivated and that only the translocation to an active X-chromosome
leads to development of synovial sarcoma. Population-based cancer registry data from the SEER program support this
hypothesis.
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Synovial sarcoma (SS) is a malignant soft tissue tumour with a
slight male predominance and accounts for approximately 7–
10% of all soft tissue sarcomas. The histogenesis of this tumour
is still unknown. The tumour can develop at any age (Weiss and
Goldblum, 2001). According to United States National Cancer
Institute Surveillance, Epidemiology, and End Results (SEER) data
for 1973–1998 (2001), the incidence of this tumour is roughly one
per million adults.
More than 95% of SS cases demonstrate a characteristic t(X;18)
translocation involving the SYT gene on chromosome 18 and SSX
genes on the X chromosome (dos Santos et al, 2001). Both SYT
and SSX proteins appear to play a role in transcriptional regula-
tion. The SSX gene family consists of at least six related and
closely linked genes located at Xp11.2. Most cases of SS studied
for the translocation have been found to have either SYT-SSX1
or SYT-SSX2 fusion transcripts. It has been shown that the trans-
location-derivative chromosome 18 or SSX-SYT fusion gene may
be lost during tumour development (Smith et al, 1987; Molenaar
et al, 1989), indicating that only the SYT-SSX fusion gene on the
X-chromosome is essential for tumorigenesis.
Considering the high frequency and speciﬁcity of the t(X;18)
translocation in SS, the SYT-SSX fusion gene is the likely causal
mutation for SS. Since females have two X-chromosomes, we
would expect that they would be twice as likely as males to devel-
op a t(X;18) translocation. This observation has been made in
alveolar soft part sarcoma, a female predominance tumour in
which a speciﬁc t(X;17) translocation was recently identiﬁed
(Ladanyi et al, 2001). However, the observed incidence rates of
SS in the population-based SEER data do not reﬂect a female
predominance. Instead the male-to-female ratio of age-standar-
dised incidence rates is 1.1:1. This observation prompted us to
investigate the possible role that X-inactivation plays in explaining
this discordance.
Although the mechanism of X-inactivation remains largely a
mystery, recent advances provide a better understanding of this
phenomenon. The X inactive-speciﬁc transcript gene (Xist) located
within the X-inactivation center (Xic) on the long arm of the X
chromosome plays a central role in X-inactivation. This process
is initiated in Xic and then spreads across the entire X-chromo-
some. X-inactivation can spread as far as 100 Mb into the
attached autosomal segment of an X;autosome translocation
(White et al, 1998). Inactivation can also spread into an autosome
from Xist-containing transgenes (Lee et al, 1996). Since the avail-
able data show that the causal translocation fusion gene for SS is
located on chromosome X (Smith et al, 1987; Molenaar et al,
1989), we hypothesise that those SYT-SSX fusion transcripts
located on the inactivated X-chromosome are non-tumorigenic.
This inactivation, therefore, reduces the likelihood of SS develop-
ment in females to the same level as that of males and provides
an explanation for the nearly balanced male:female ratio observed
in SS. In the current study, we utilised SEER incidence data to test
our hypothesis.
MATERIALS AND METHODS
Age-speciﬁc and sex-speciﬁc SS incidence data (shown in Table 1)
were derived from SEER Program Public-Use Data (2001). A total
of 680 SS cases (ICDO morphology codes 9040, 9041, 9042, and
9043) were diagnosed in 11 SEER registry regions providing data
for some or all of the years 1973 to 1998. Since the observed male
and female population counts differ within each age group, we age-
adjusted the observed male and female case counts in each age
group (see footnote in Table 1). We summed the age-speciﬁc
numbers to obtain a total adjusted count of cases for males and
for females. Total observed male and female cases were then
utilised to calculate the observed proportion. In the current study,
we did not analyse the data according to race or geographical
region due to the limited number of cases.
A Z test was used to determine whether the observed proportion
of male cases (standardised to the average person-years distribu-
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www.bjcancer.comtion) differed signiﬁcantly from the expected proportion based on
the hypothesis of X-inactivation and the alternative competing
hypothesis of no inactivation (see Appendix).
RESULTS
Age-speciﬁc incidence rates of SS among males and females and
the number of SS cases by sex in the 11 SEER registries providing
data for some or all of the years 1973 to 1998 are presented in
Table 1. The observed proportion of male cases standardised to
the average population distribution for males and females is
362.8/(362.8+317.7)=53.3%. Under the hypothesis of X-inactiva-
tion, the expected proportion for male cases calculated from
Equation 3 is 52% and the observed and expected proportions
of male cases do not differ (Z=0.68 and P=0.5) (Appendix 1).
In contrast, under the alternative competing hypothesis of no
X-inactivation, the expected proportion for male cases is 35%,
which differs signiﬁcantly from the observed proportion (Z=10.0
and P50.00001).
DISCUSSION
Our hypothesis is conditional on one X-linked gene mutation func-
tioning as the causal event for developing SS. This one X-linked
gene mutation is biologically plausible and supported by available
data, namely, the high frequency and speciﬁcity of the t(X;18)
translocation in SS. Single chromosomal translocations resulting
in malignancy have been observed in chronic myelogenous leuke-
mia and acute promyelocytic leukemia. Studies of transgenic
mice support the oncogenic nature of the products of both fusion
transcripts (Melnick and Licht, 1999; Jaffe et al, 2001).
In the current study, we utilised population-based SEER data,
which now represent about 14% of the US population, to test
our hypothesis. Although several relatively large SS case series have
been reported in the literature, they are not population based and,
thus, are not appropriate for our analysis. Most of those case series
come from several major tertiary care cancer hospitals and are
subject to ascertainment bias.
X-inactivation can spread into the attached autosomal segment of
an X;autosome translocation or into an autosome from Xist-
containing transgenes (Lee et al, 1996; White et al, 1998). White et
al (1998) showed that most of the translocated autosomal genes or
expressed sequence tags (EST) are subject to inactivation, but a small
percentage may escape. Although we have no evidence that the
lesional SYT-SSX transcript falls into this latter category, the results
from our study should be interpreted with caution. A well-designed
molecular study may better delineate this issue. A recently reported
X-inactivation proﬁle of the human X-chromosome included the
expression of 224 X-linked genes and ESTs by reverse-transcrip-
tion-PCR analysis (Carrel et al, 1999). However, SSX genes were
not included possibly because normal expression is limited to very
few human tissues such as testis and thyroid or there are multiple
copies of SSX genes (Crew et al, 1995; Fligman et al, 1995). However,
all the ﬂanking genes or ESTs of the SSX1 or SSX2 genes were subject
to inactivation, further supporting our hypothesis.
In conclusion, we provide population-based evidence supporting
a decisive role for X-inactivation in the fate of an oncogenic chro-
mosomal translocation fusion transcript. Although females have
approximately twice the risk for developing the t(X;18) translocation
as do males, their actual risk for developing SS is similar to that of
males probably due to X-inactivation. Conﬁrmation of an X-inacti-
vation hypothesis in SS must await studies at the molecular level.
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Table 1 Synovial sarcoma incidence in Surveillance, Epidemiology, and End Results (SEER) registries, 1973–1998
Males Females
Age group
(years) No. cases
Age-speciﬁc incidence
rate/100 000 No. cases
Age-speciﬁc incidence
rate/100 000
Adjusted No.
male cases
a
Adjusted No.
female cases
a
0–4 3 0.01 2 0.01 2.9 2.0
5–9 8 0.03 7 0.03 7.8 7.2
10–14 28 0.11 25 0.10 27.4 25.6
15–19 39 0.15 23 0.09 38.2 23.5
20–24 35 0.13 38 0.14 34.6 38.5
25–29 46 0.16 47 0.17 45.8 47.3
30–34 32 0.11 40 0.14 32.1 39.9
35–39 34 0.13 30 0.12 34.2 29.9
40–44 27 0.12 22 0.10 27.4 21.7
45–49 24 0.13 13 0.07 24.4 12.8
50–54 22 0.14 17 0.10 22.5 16.6
55–59 18 0.13 9 0.06 18.7 8.7
60–64 15 0.12 9 0.06 15.9 8.5
65–69 9 0.08 14 0.11 10.0 12.8
70–74 8 0.10 13 0.12 9.3 11.4
75–79 7 0.12 8 0.09 8.8 6.7
80–84 2 0.06 5 0.09 2.8 3.9
585 0 0.00 1 0.02 0.0 0.7
Total 357 323 362.8 317.7
aAdjusted numbers of cases were calculated by applying sex-speciﬁc and age-speciﬁc incidence rates to a standard population obtained by summing
the male and female populations at risk over the entire time period in each age group and dividing by 2.
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APPENDIX 1
Calculation of the expected male and female proportions in
SS cases.
In order to estimate the expected male and female proportions of
SS cases, we ﬁrst estimated the expected probabilities of developing
t(X;18) translocations for males and females.
Should a chromosomal translocation develop in a cell, the
conditional probabilities for such a translocation being a SYT-
SSX translocation are:
ProbfSYT ÿ SSX=tCf 
SSYT
Gf

SSSX
Gf
1
and
ProbmSYT ÿ SSX=tCm 
SSYT
Gm

SSSX
Gm
2
where S, G, and C are target gene size, total human genome size,
and constant, respectively, and m and f are males and females. A
factor of two, for two copies of the SSSX gene in females, is
cancelled out by X-inactivation; therefore, this factor is not
included. If we assume Cf =Cm, then the expected proportion of
male cases will be
ProbmSYT ÿ SSX=t
ProbmSYT ÿ SSX=tProbfSYT ÿ SSX=t

GfGf
GfGf  I  GmGm
3
where I=1 for the hypothesis of X-inactivation and I=2 for the
alternative competing hypothesis of no X-inactivation. The total
human genome sizes for males and females were obtained from
the most recent publication of the Human Genome Project (Inter-
national Human Genome Sequencing Consortium, 2001). Note
that the terms on the right-hand side of the Equation 3 are only
dependent on the male and female genome sizes. This statement
theoretically holds for other chromosomal translocations.
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